241 related articles for article (PubMed ID: 25936882)
1. [Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
Wang Q; Li M; Hu C
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):193-8. PubMed ID: 25936882
[TBL] [Abstract][Full Text] [Related]
2. 5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
Yang B; Yang ZG; Gao B; Shao GG; Li GH
Int J Clin Exp Pathol; 2015; 8(10):12961-6. PubMed ID: 26722491
[TBL] [Abstract][Full Text] [Related]
3. [Effect of SLC7A11 gene downregulation on the gefitinib resistance of lung adenocarcinoma PC9/GR cells and its mechanism].
Jia YL; Zhao Y; Zhen SM; Cheng ZS; Zheng BY; Liu YP; Liu LH
Zhonghua Zhong Liu Za Zhi; 2023 Sep; 45(9):779-786. PubMed ID: 37805442
[No Abstract] [Full Text] [Related]
4. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
5. [Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].
Ju LX; Zhou CC; Tang L; Zhao YM; Yang XJ; Su B; Meng SY; Li W; Yan LH; Ding YM
Zhonghua Jie He He Hu Xi Za Zhi; 2010 May; 33(5):354-8. PubMed ID: 20646614
[TBL] [Abstract][Full Text] [Related]
6. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
7. Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance.
Lin CC; Chen JT; Lin MW; Chan CH; Wen YF; Wu SB; Chung TW; Lyu KW; Chou HC; Chan HL
Toxicol Appl Pharmacol; 2015 Nov; 288(3):359-73. PubMed ID: 26298006
[TBL] [Abstract][Full Text] [Related]
8. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
[TBL] [Abstract][Full Text] [Related]
9. An activation of LC3A-mediated autophagy contributes to de novo and acquired resistance to EGFR tyrosine kinase inhibitors in lung adenocarcinoma.
Nihira K; Miki Y; Iida S; Narumi S; Ono K; Iwabuchi E; Ise K; Mori K; Saito M; Ebina M; Sato I; Maemondo M; Yamada-Okabe H; Kondo T; Sasano H
J Pathol; 2014 Oct; 234(2):277-88. PubMed ID: 24687913
[TBL] [Abstract][Full Text] [Related]
10. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Lee Y; Choi YR; Kim KY; Shin DH
Oncotarget; 2016 Jul; 7(28):43315-43323. PubMed ID: 27270313
[TBL] [Abstract][Full Text] [Related]
11. CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines.
Maeda M; Murakami Y; Watari K; Kuwano M; Izumi H; Ono M
Lung Cancer; 2015 Mar; 87(3):265-71. PubMed ID: 25638724
[TBL] [Abstract][Full Text] [Related]
12. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor-1 receptor inhibition overcomes gefitinib resistance in mucinous lung adenocarcinoma.
Hurbin A; Wislez M; Busser B; Antoine M; Tenaud C; Rabbe N; Dufort S; de Fraipont F; Moro-Sibilot D; Cadranel J; Coll JL; Brambilla E
J Pathol; 2011 Sep; 225(1):83-95. PubMed ID: 21598249
[TBL] [Abstract][Full Text] [Related]
14. Favorable effect of the combination of vinorelbine and dihydropyrimidine dehydrogenase‑inhibitory fluoropyrimidine in EGFR‑mutated lung adenocarcinoma: retrospective and in vitro studies.
Izumi H; Touge H; Igishi T; Makino H; Nishii-Ito S; Takata M; Nakazaki H; Ueda Y; Matsumoto S; Kodani M; Kurai J; Takeda K; Sakamoto T; Yanai M; Tanaka N; Nirodi CS; Shimizu E
Int J Oncol; 2015 Mar; 46(3):989-98. PubMed ID: 25573239
[TBL] [Abstract][Full Text] [Related]
15. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
[TBL] [Abstract][Full Text] [Related]
17. Slug confers resistance to the epidermal growth factor receptor tyrosine kinase inhibitor.
Chang TH; Tsai MF; Su KY; Wu SG; Huang CP; Yu SL; Yu YL; Lan CC; Yang CH; Lin SB; Wu CP; Shih JY; Yang PC
Am J Respir Crit Care Med; 2011 Apr; 183(8):1071-9. PubMed ID: 21037017
[TBL] [Abstract][Full Text] [Related]
18. Suppression of Mig-6 overcomes the acquired EGFR-TKI resistance of lung adenocarcinoma.
Kang DH; Jung SS; Yeo MK; Lee DH; Yoo G; Cho SY; Oh IJ; Kim JO; Park HS; Chung C; Lee JE
BMC Cancer; 2020 Jun; 20(1):571. PubMed ID: 32552717
[TBL] [Abstract][Full Text] [Related]
19. Genome-wide profiling of micro-RNA expression in gefitinib-resistant human lung adenocarcinoma using microarray for the identification of miR-149-5p modulation.
Hu Y; Qin X; Yan D; Cao H; Zhou L; Fan F; Zang J; Ni J; Xu X; Sha H; Liu S; Yu S; Wu J; Ma R; Feng J
Tumour Biol; 2017 Mar; 39(3):1010428317691659. PubMed ID: 28345454
[TBL] [Abstract][Full Text] [Related]
20. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
Xie M; Zhang L; He CS; Xu F; Liu JL; Hu ZH; Zhao LP; Tian Y
J Cell Biochem; 2012 May; 113(5):1501-13. PubMed ID: 22173954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
